A comparative study of smica in various body fluids of diagnosed cervical cancer patients and healthy women
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Cervical cancer (CC) is a major public health problem in women, and its early detection can help reduce morbidity and mortality. The objective of this study was to compare serum levels of soluble major histocompatibility complex class I-related chain A (sMICA) levels in various body fluids between women diagnosed with CC and healthy women. Methods: A case-control study was conducted at a tertiary care hospital and a cancer center in Kolhapur, India. Overall, 150 individuals (100 CC patients and 50 healthy women) participated after providing informed written consent. Demographic data, histopathology history, parity, and tumor, node, and metastasis (TNM) staging data were collected. Pap smears, saliva, blood, and urine samples were collected. Pap smears were examined microscopically, and sMICA levels in all samples were determined by enzyme-linked immunoassay (ELISA). Results: The mean age of women with cervical cancer was 49.86±8.18 years. Squamous cell carcinoma (70%) was the most common histological variant in CC patients. Serum soluble sMICA levels differed significantly with parity and TNM staging (P<0.05). Mean levels of sMICA were significantly different in samples (CC cases vs. healthy patients; saliva: 166.721±108.718 vs. 0.039±0.005 pg/mL; urine: 82.921±45.580 vs. 0.010±0.005 pg/mL; serum: 35.756±10.799 vs. 0.039±0.005 pg/mL, P<0.001). Conclusion: Levels of sMICA in body fluids can be considered as a diagnostic or prognostic tool to determine disease progression or tumor regression.
Abstract
Objective: Cervical cancer (CC) is a major public health problem in women, and its early detection can help reduce morbidity and mortality. The objective of this study was to compare serum levels of soluble major histocompatibility complex class I-related chain A (sMICA) levels in various body fluids between women diagnosed with CC and healthy women. Methods: A case-control study was conducted at a tertiary care hospital and a cancer center in Kolhapur, India. Overall, 150 individuals (100 CC patients and 50 healthy women) participated after providing informed written consent. Demographic data, histopathology history, parity, and tumor, node, and metastasis (TNM) staging data were collected. Pap smears, saliva, blood, and urine samples were collected. Pap smears were examined microscopically, and sMICA levels in all samples were determined by enzyme-linked immunoassay (ELISA). Results: The mean age of women with cervical cancer was 49.86±8.18 years. Squamous cell carcinoma (70%) was the most common histological variant in CC patients. Serum soluble sMICA levels differed significantly with parity and TNM staging (P<0.05). Mean levels of sMICA were significantly different in samples (CC cases vs. healthy patients; saliva: 166.721±108.718 vs. 0.039±0.005 pg/mL; urine: 82.921±45.580 vs. 0.010±0.005 pg/mL; serum: 35.756±10.799 vs. 0.039±0.005 pg/mL, P<0.001). Conclusion: Levels of sMICA in body fluids can be considered as a diagnostic or prognostic tool to determine disease progression or tumor regression.
참고문헌 (19)
- Srivastava AN, "Cervical cancer screening in rural India : status & current concepts", Indian J Med Res, 148, pp.687~696 (2018)
- Arbyn M, "Estimates of incidence and mortality of cervical cancer in 2018 : a worldwide analysis", Lancet Glob Health, 8, pp.e191~203 (2020)
- Bobdey S, "Burden of cervical cancer and role of screening in India", Indian J Med Paediatr Oncol, 37, pp.278~285 (2016)
- Parish SJ, "Impact of vulvovaginal health on postmenopausal women : a review of surveys on symptoms of vulvovaginal atrophy", Int J Womens Health, 5, pp.437~447 (2013)
- Dalal PK, "Postmenopausal syndrome", Indian J Psychiatry, 57(Suppl 2), pp.S222~S232 (2015)
- Catarino R, "Cervical cancer screening in developing countries at a crossroad : emerging technologies and policy choices", World J Clin Oncol, 6, pp.281~290 (2015)
- WHO guidelines, "WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention", World Health Organization, ~ (2013)
- World Health Organization, "Comprehensive cervical cancer control: a guide to essential practice. 2nd ed", World Health Organization, ~ (2014)
- Mishra GA, "An overview of prevention and early detection of cervical cancers", Indian J Med Paediatr Oncol, 32, pp.125~132 (2011)
- Baranwal AK, "Major histocompatibility complex class i chain-related a(MICA)molecules : relevance in solid organ transplantation", Front Immunol, 8, pp.182~ (2017)
- Zhao Y, "Prognostic value of MICA", B in cancers : a systematic review and meta-analysis, 2017, pp.8, 96384~96395
- Samuels S, "High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma", Tissue Antigens, 85, pp.476~483 (2015)
- Safaeian M, "Cervical cancer prevention--cervical screening : science in evolution", Obstet Gynecol Clin North Am, 34, pp.739~760 (2007)
- Sreedevi A, "Epidemiology of cervical cancer with special focus on India", Int J Womens Health, 7, pp.405~414 (2015)
- Mhaske M, "Study of association of some risk factors & cervical dysplasia", cancer among rural women, 2011, pp.2, 209~212
- Wang W, "Image-guided, intensity-modulated radiation therapy in definitive radiotherapy for 1433 patients with cervical cancer", Gynecol Oncol, 151, pp.444~448 (2018)
- Kashyap N, "Risk factors of cervical cancer : a case-control study", Asia Pac J Oncol Nurs, 6, pp.308~314 (2019)
- Vinh-Hung V, "Prognostic value of histopathology and trends in cervical cancer : a SEER population study", BMC Cancer, 7, pp.164~ (2007)
- Schmiedel D, "NKG2D ligands-critical targets for cancer immune escape and therapy", Front Immunol, 9, pp.2040~ (2018)